Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. - Jaramillo, Sonia; Krisam, Johannes; Le Cornet, Lucian; Kratzmann, Markus; Baumann, Lukas; Sauer, Tim; Crysandt, Martina; Rank, Andreas; Behringer, Dirk; Teichmann, Lino; Görner, Martin; Trappe, Ralf-Ulrich; et al. (Trials, 2021)